Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Excessive stimulation of AMPA type ionotropic glutamate receptors is increasingly implicated in the development and maintenance of several debilitating human CNS disorders. Preliminary results of Phase II clinical trials have shown that talampanel, a new negative allosteric modulator of AMPA receptors with homophthalazine (2,3-benzodiazepine) chemical structure, can be useful for the treatment of epilepsy and might alleviate dyskinesia in levodopa-treated patients with Parkinson's disease. Data of animal experiments give promise that talampanel might also be suitable for the treatment of ischaemic stroke and multiple sclerosis and might also suppress tumor growth in the CNS that makes this chemical structure an exciting new field of pharmaceutical research.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalDrug Discovery Today: Therapeutic Strategies
Volume1
Issue number1
DOIs
Publication statusPublished - Sep 2004

Fingerprint

GYKI 53405
AMPA Receptors
Pharmacology
Ionotropic Glutamate Receptors
Phase II Clinical Trials
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Dyskinesias
Levodopa
Benzodiazepines
Multiple Sclerosis
Parkinson Disease
Epilepsy
Stroke
Therapeutics
Growth
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

@article{32a491f0b7794f2f8e1541af09d4a554,
title = "Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors",
abstract = "Excessive stimulation of AMPA type ionotropic glutamate receptors is increasingly implicated in the development and maintenance of several debilitating human CNS disorders. Preliminary results of Phase II clinical trials have shown that talampanel, a new negative allosteric modulator of AMPA receptors with homophthalazine (2,3-benzodiazepine) chemical structure, can be useful for the treatment of epilepsy and might alleviate dyskinesia in levodopa-treated patients with Parkinson's disease. Data of animal experiments give promise that talampanel might also be suitable for the treatment of ischaemic stroke and multiple sclerosis and might also suppress tumor growth in the CNS that makes this chemical structure an exciting new field of pharmaceutical research.",
author = "G. Sz{\'e}n{\'a}si and L. H{\'a}rsing",
year = "2004",
month = "9",
doi = "10.1016/j.ddstr.2004.08.018",
language = "English",
volume = "1",
pages = "69--76",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors

AU - Szénási, G.

AU - Hársing, L.

PY - 2004/9

Y1 - 2004/9

N2 - Excessive stimulation of AMPA type ionotropic glutamate receptors is increasingly implicated in the development and maintenance of several debilitating human CNS disorders. Preliminary results of Phase II clinical trials have shown that talampanel, a new negative allosteric modulator of AMPA receptors with homophthalazine (2,3-benzodiazepine) chemical structure, can be useful for the treatment of epilepsy and might alleviate dyskinesia in levodopa-treated patients with Parkinson's disease. Data of animal experiments give promise that talampanel might also be suitable for the treatment of ischaemic stroke and multiple sclerosis and might also suppress tumor growth in the CNS that makes this chemical structure an exciting new field of pharmaceutical research.

AB - Excessive stimulation of AMPA type ionotropic glutamate receptors is increasingly implicated in the development and maintenance of several debilitating human CNS disorders. Preliminary results of Phase II clinical trials have shown that talampanel, a new negative allosteric modulator of AMPA receptors with homophthalazine (2,3-benzodiazepine) chemical structure, can be useful for the treatment of epilepsy and might alleviate dyskinesia in levodopa-treated patients with Parkinson's disease. Data of animal experiments give promise that talampanel might also be suitable for the treatment of ischaemic stroke and multiple sclerosis and might also suppress tumor growth in the CNS that makes this chemical structure an exciting new field of pharmaceutical research.

UR - http://www.scopus.com/inward/record.url?scp=13444261143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444261143&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2004.08.018

DO - 10.1016/j.ddstr.2004.08.018

M3 - Article

AN - SCOPUS:13444261143

VL - 1

SP - 69

EP - 76

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

IS - 1

ER -